Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Organon & Co. (OGN)
Company Research
Source: Business Wire
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)--Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candidates, including HLX11. The agreement licenses the global commercialization rights for the product, except for China, to Organon.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240930000839/en/The multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a neoadjuvant therapy in patients with HER2-positive, HR-negative early, or locally advanced breast cancer as part of a complete treatment regimen. E
Show less
Read more
Impact Snapshot
Event Time:
OGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OGN alerts
High impacting Organon & Co. news events
Weekly update
A roundup of the hottest topics
OGN
News
- Organon To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceBusiness Wire
- FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderBusiness Wire
- Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]Yahoo! Finance
- Organon & Co. (OGN): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]Yahoo! Finance
OGN
Earnings
- 10/31/24 - Beat
OGN
Sec Filings
- 12/23/24 - Form 8-K
- 12/6/24 - Form 8-K
- 11/8/24 - Form 4
- OGN's page on the SEC website